Physician profile
Khalil Diab
NPI 1528230109
$10,420.23
in general payments reported to CMS, 2019-2025
23 companies · $1,439 in 2025
The $1,439 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.62 · 2020: $244 · 2021: $3,763 · 2022: $2,096 · 2023: $1,517 · 2024: $1,350 · 2025: $1,439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,310 · Consulting Fee: $750 · Travel and Lodging: $746 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,310.36 |
| Consulting Fee | $750.00 |
| Travel and Lodging | $745.54 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,300.75 | 2021-2025 | Tezspire, Airsupra, Fasenra |
| Ethicon INC. | $1,489.43 | 2020-2022 | |
| Medical Device Business Services, INC. | $803.54 | 2024 | Monarch |
| Ambu A/S | $590.00 | 2021 | |
| Zoll Medical Corporation | $544.67 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $400.18 | 2024-2025 | Glassia |
| Novocure Gmbh | $316.67 | 2021 | |
| Pulmonx Corporation | $290.53 | 2021-2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Insmed, INC. | $232.58 | 2020-2021 | |
| Grifols USA, LLC | $231.60 | 2023-2024 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $220.08 | 2020-2023 | Yupelri |
| Glaxosmithkline, LLC. | $177.69 | 2021-2022 | |
| Astrazeneca Uk Limited | $145.53 | 2023-2024 | Tezspire |
| Amgen INC. | $144.88 | 2023 | Tezspire |
| Jazz Pharmaceuticals INC. | $143.98 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $117.31 | 2021 | |
| Galvanize Therapeutics, INC | $91.63 | 2025 | Aliya System |
| Csl Behring | $66.40 | 2021 | |
| Vifor Pharma, INC. | $59.66 | 2024-2025 | Zemaira |
| Lilly USA, LLC | $22.01 | 2025 | Zepbound |
| Boston Scientific Corporation | $19.49 | 2024 | Acquire |
| Sunovion Pharmaceuticals INC. | $11.62 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khalil Diab listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.